Inspire Medical Systems (NYSE:INSP) Shares Down 3.9% – Here’s What Happened

Shares of Inspire Medical Systems, Inc. (NYSE:INSP) dropped 3.9% during trading on Tuesday . The stock traded as low as $95.12 and last traded at $94.0950. Approximately 38,444 shares were traded during trading, a decline of 96% from the average daily volume of 931,827 shares. The stock had previously closed at $97.93.

Key Inspire Medical Systems News

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Zacks argues investors should retain INSP, citing strong Inspire V clinical data, improving reimbursement visibility and cost control that support longer?term fundamentals. Read More.
• Positive Sentiment: An MSN/MarketWatch item reports a 12.65% increase in INSP’s consensus price target to $144.32, a potentially supportive signal for medium?term valuation expectations. Read More.
• Neutral Sentiment: A comparative piece contrasts Inspire with EUDA Health (EUDA) — useful for investors sizing relative opportunities but not directly moving INSP shares. Read More.
• Negative Sentiment: Bernstein Litowitz filed a securities?class action in SDNY alleging misleading statements by Inspire and certain executives; the suit follows a major share drop tied to reported product delays. Litigation increases legal exposure and investor uncertainty. Read More.
• Negative Sentiment: Multiple law firms (Faruqi & Faruqi, Levi & Korsinsky, Bleichmar Fonti & Auld, Rosen Law, Glancy Prongay, Hagens Berman, Schall, Gross, Bronstein, etc.) have issued investor alerts or filed suits and are soliciting lead plaintiffs ahead of a Jan 5, 2026 deadline — a coordinated legal response that amplifies short?term downside risk. Read More.
• Negative Sentiment: Investor alerts tie the litigation to alleged concealed Medicare?billing software failures and an Inspire V inventory glut — these operational issues are the proximate cause of the stock’s sharp sell?off and ongoing volatility. Read More.

Analysts Set New Price Targets

A number of equities research analysts recently commented on INSP shares. Stifel Nicolaus set a $110.00 price objective on shares of Inspire Medical Systems and gave the stock a “buy” rating in a report on Monday, November 24th. Evercore ISI reduced their price objective on Inspire Medical Systems from $150.00 to $125.00 and set an “outperform” rating for the company in a research report on Tuesday, October 7th. Morgan Stanley reissued an “equal weight” rating and issued a $130.00 target price (up previously from $105.00) on shares of Inspire Medical Systems in a research report on Tuesday, December 2nd. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Inspire Medical Systems in a research report on Wednesday, December 10th. Finally, KeyCorp reiterated a “sector weight” rating on shares of Inspire Medical Systems in a report on Tuesday, November 4th. Eleven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $139.00.

Inspire Medical Systems Stock Performance

The stock has a market cap of $2.75 billion, a price-to-earnings ratio of 64.40, a price-to-earnings-growth ratio of 11.12 and a beta of 0.69. The company has a 50-day simple moving average of $99.98 and a two-hundred day simple moving average of $102.96.

Inspire Medical Systems (NYSE:INSP) last released its earnings results on Monday, November 3rd. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.53. The business had revenue of $224.50 million during the quarter, compared to analysts’ expectations of $220.39 million. Inspire Medical Systems had a net margin of 5.05% and a return on equity of 9.41%. The firm’s revenue was up 10.5% on a year-over-year basis. During the same period last year, the business earned $0.60 earnings per share. As a group, sell-side analysts predict that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.

Insider Buying and Selling at Inspire Medical Systems

In other news, Director Shawn Mccormick sold 2,000 shares of the company’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $127.48, for a total value of $254,960.00. Following the sale, the director directly owned 26,046 shares of the company’s stock, valued at approximately $3,320,344.08. This represents a 7.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Inspire Medical Systems

A number of institutional investors have recently bought and sold shares of INSP. Quarry LP boosted its stake in shares of Inspire Medical Systems by 2,127.3% during the 1st quarter. Quarry LP now owns 245 shares of the company’s stock worth $39,000 after acquiring an additional 234 shares during the period. Banque Transatlantique SA acquired a new stake in Inspire Medical Systems during the 1st quarter valued at $46,000. Manning & Napier Advisors LLC bought a new position in Inspire Medical Systems during the third quarter worth $32,000. Smartleaf Asset Management LLC increased its holdings in shares of Inspire Medical Systems by 27.2% in the first quarter. Smartleaf Asset Management LLC now owns 454 shares of the company’s stock valued at $71,000 after purchasing an additional 97 shares during the last quarter. Finally, Daiwa Securities Group Inc. increased its holdings in shares of Inspire Medical Systems by 38.7% in the second quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock valued at $60,000 after purchasing an additional 130 shares during the last quarter. Institutional investors and hedge funds own 94.91% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.